As an investor, deciding whether the IPO is Good or Bad to invest in can often be challenging. If you are confused and worried about whether to Apply or Not the Anthem Biosciences IPO. Then worry not, here we are describing 10 important key points & an in-depth, detailed Anthem Biosciences IPO review which will help you to make the decision.
Strengths and Weaknesses of Anthem Biosciences IPO
Strengths:
- Anthem Biosciences Limited is one of the growing providers of international recruitment solutions with a strong experience in serving global higher education institutions.
- The company focuses on developing innovative solutions that allow it to offer a wide range of advanced, technology-driven solutions across different methods and manufacturing practices.
- The company consists of different business models that serve the needs of small pharmaceutical and emerging biotech companies, covering everything from discovery to commercial manufacturing.
- Anthem Biosciences has maintained a strong, long-term relationship with a large, diverse, and loyal customer base.
Weaknesses:
- In FY25, 81.65% of the company’s revenue is largely dependent on CRDMO services. If their CRDMO customers or the industries face any issues, then it can badly impact the company’s business, financial condition, and cash flow.
- In their industry, technology is changing very fast, meaning they need to constantly develop new technologies to stay competitive in the market; if they fail to do so can negatively affect the business goals and overall financial condition.
- Anthem Biosciences is highly regulated, meaning it needs to get, maintain, and renew various licenses and approvals to run successfully. If it fails to do so can badly impact its business operations and cash flow.
- The company gets mostly 70.92% of its revenue from the top 5, and 77.33% of revenue comes from the top 10 customers, meaning losing any of these customers or earning less from them can lead to issues like business loss and overall financial condition.
Anthem Biosciences IPO Details
| IPO Size | ₹3,395 crores |
| Offer-for-sale | 5,95,61,404 equity shares |
| Fresh issue | – |
| Price band | ₹540 to ₹570 |
| Subscription | Opens on July 14, 2025, and the closing date is July 16, 2025 |
| Purpose of IPO | Offer-for-Sale |
Anthem Biosciences IPO Open and closing dates?
Anthem Biosciences IPO will be opening for subscription on July 14, 2025, and will be closed for subscription on July 16, 2025.
What is the size of the Anthem Biosciences IPO?
The company planned to raise funds of around ₹3,395 crores via IPO. This IPO comprises entirely an Offer-for-sale up to 5,95,61,404 equity shares with a face value of ₹2 each.
What are the subscription details of the Anthem Biosciences IPO?
The Anthem Biosciences IPO price range is set at ₹540 to ₹570 per share. In this IPO, a total of 26 shares were available in 1 lot size for the minimum Retail category. For the maximum Retail category, 338 shares were available in 13 lot sizes. Additionally, 364 shares were available in 14 lot sizes for the S-HNI Minimum category. While for the B-HNI Minimum category, 1,768 shares were available in 68 lot sizes.
To invest in this IPO, each investor category has specific investment amounts:
- Retail Investors: Minimum investment of ₹14,820 and maximum investment of ₹1,92,660.
- Small HNI (S-HNI): Minimum investment of ₹2,07,480.
- Big HSI (S-HNI): A minimum investment of ₹10,07,760 is required.
What is the Anthem Biosciences IPO listing Date?
Anthem Biosciences is a Mainboard IPO shares will be listed on July 21, 2025, on the BSE (Bombay Stock Exchange) & NSE (National Stock Exchange).
About Anthem Biosciences
Incorporated in 2006, Anthem Biosciences Limited is one of the leading innovation-driven and technology-focused Contract Research, Development and Manufacturing Organizations (“CRDMO”) with end-to-end operations covering drug discovery, development, and manufacturing. Anthem Biosciences is one of the few companies in India with Integrated capabilities in New Chemical Entities (NCE) and New Biological Entities (NBE) throughout drug discovery, development, and commercial manufacturing. They are one of the leading companies involved in offering a comprehensive range of customers such as emerging biotech companies and large pharmaceutical firms around the world. The company has supplied to over 150 customers, from small biotech to large pharmaceutical companies, as of March 31, 2024. Currently, the company has a team of 600 employees, including medicinal chemists, microbiologists, molecular biologists, biochemists, and chemical engineers. The company is involved in the manufacturing of specialized fermentation-based APIs, including probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars.
What are the Objectives of the Crizac Limited IPO?
The proceeds raised from the Offer-for-sale will be received by the Selling Shareholders after deduction of Offer-related expenses and relevant taxes thereon, to be borne by the respective Selling Shareholders.
Anthem Biosciences IPO Financials
The company reported revenue of ₹1,930.29 crores in 2025 against ₹1,483.07 crores in 2024. The company reported a profit of ₹451.26 crores in 2025 against a profit of ₹367.31 crores in 2024.
Anthem Biosciences IPO Promoters
Ajay Bhardwaj, Ganesh Sambasivam, K Ravindra Chandrappa, and Ishaan Bhardwaj are the promoters of the company.
Who are the Anthem Biosciences IPO lead managers and registrar?
Jm Financial Limited, Citigroup Global Markets India Private Limited, J.P. Morgan India Private Limited, Nomura Financial Advisory And Securities (India) Pvt Ltd are Anthem Biosciences’s lead managers, while KFin Technologies Limited is the company’s registrar.
Should you apply or not for the Anthem Biosciences IPO?
Your investment goal and risk appetite depend on whether you should apply for the Anthem Biosciences IPO. Anthem Biosciences is one of the leading technology-focused CRDMO (Contract Research, Development, and Manufacturing Organization) whose have a strong focus on innovation, a differentiated business model, and long-standing relationships with a wide range of customers. They are one of the youngest Indian CRDMOs in India, with generated ₹10,000 million of revenue within 14 years of operations. The company is recorded as generating the highest revenue providing company compared to its peers in India. Now, if we see its positive side, over the years, the company has shown an excellent growth trajectory, advanced service offering across the drug lifecycle, and a leadership position in the Indian CRDMO market.
So, now the question is, should you apply or not for the Anthem Biosciences IPO? If you are an investor who is planning to invest in this company with a long-term goal, then the Anthem Biosciences IPO can be a good opportunity to invest in. The incredible combination of solid financial and well-defined growth strategy in offering makes it an attractive player in the pharmaceutical and biotech space makes Anthem Biosciences an attractive investment choice. However, we recommend always doing a good financial background check on the company you want to invest in, and investing in it at your own risk.
